Inside the Strategy Room cover image

159. Voices of CEO Excellence: Merck’s Ken Frazier. Episode 1

Inside the Strategy Room

00:00

The Importance of R&D in Pharmaceutical CEOs

A Wall Street analyst report said pharmaceutical CEOs should stop investing in R&D and invest in non-farma assets. Merck had five-year earnings guidance, which only two of those five years had elapsed when I took over. "I felt very strongly that if Merck was going to be an R&D focus company, this was the moment of truth for us," he says.

Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner